Navigation
Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
Archive: November 12, 2021
Home
2021
November
12
12
Nov
2021
Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of
nab
-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
0
0
November 12, 2021
November 12, 2021
